Evidence map›Paper›PMID 40301562›Full record

ArticleNature medicine2025

Author Correction: Autologous T cell therapy for PRAME

Martin Wermke, Dejka M Araujo, Manik Chatterjee, Apostolia M Tsimberidou, Tobias A W Holderried, Amir A Jazaeri, Ran Reshef, Carsten Bokemeyer, Winfried Alsdorf, Katrin Wetzko and 30 more

Abstract readPublished Erratum
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Adoptive T-Cell Therapy in Sarcomas.Current oncology reports · 2025
    Review
  3. The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.American journal of clinical dermatology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors.

Martin WermkeDepartment of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-4844-4087
Dejka M AraujoDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manik ChatterjeeComprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
Apostolia M TsimberidouDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tobias A W HolderriedDepartment of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-2474-523X
Amir A JazaeriDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4335-4151
Ran ReshefColumbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2185-9546
Carsten BokemeyerDepartment of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Winfried AlsdorfDepartment of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0002-3018-2437
Katrin WetzkoDepartment of Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
Peter BrossartDepartment of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.
Katrin AslanImmatics Biotechnologies GmbH, Tübingen, Germany.
Linus BackertImmatics Biotechnologies GmbH, Tübingen, Germany.
Sebastian BunkImmatics Biotechnologies GmbH, Tübingen, Germany.
Jens FritscheImmatics Biotechnologies GmbH, Tübingen, Germany.ORCID http://orcid.org/0000-0002-5557-8577
Swapna GuldeImmatics Biotechnologies GmbH, Tübingen, Germany.
Silvana HenglerImmatics Biotechnologies GmbH, Tübingen, Germany.ORCID http://orcid.org/0000-0001-6973-0800
Norbert HilfImmatics Biotechnologies GmbH, Tübingen, Germany.ORCID http://orcid.org/0000-0002-2618-8174
Mohammad B HossainImmatics US, Inc., Houston, TX, USA.
Jens HukelmannImmatics Biotechnologies GmbH, Tübingen, Germany.
Mamta KalraImmatics US, Inc., Houston, TX, USA.
Delfi KrishnaImmatics US, Inc., Houston, TX, USA.
M Alper KursunelImmatics Biotechnologies GmbH, Tübingen, Germany.
Dominik MaurerImmatics Biotechnologies GmbH, Tübingen, Germany.
Andrea Mayer-MoklerImmatics Biotechnologies GmbH, Tübingen, Germany.
Regina MendrzykImmatics Biotechnologies GmbH, Tübingen, Germany.
Ali MohamedImmatics US, Inc., Houston, TX, USA.
Karine PozoImmatics US, Inc., Houston, TX, USA.
Arun SatelliImmatics US, Inc., Houston, TX, USA.
Marilena LetiziaImmatics Biotechnologies GmbH, Tübingen, Germany.
Heiko SchusterImmatics Biotechnologies GmbH, Tübingen, Germany.
Oliver SchoorImmatics Biotechnologies GmbH, Tübingen, Germany.
Claudia WagnerImmatics Biotechnologies GmbH, Tübingen, Germany.
Hans-Georg RammenseeInstitute of Immunology, Eberhard Karls University Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0003-1614-2647
Carsten ReinhardtImmatics Biotechnologies GmbH, Tübingen, Germany.
Harpreet Singh-JasujaImmatics Biotechnologies GmbH, Tübingen, Germany.
Steffen WalterImmatics US, Inc., Houston, TX, USA.
Toni WeinschenkImmatics Biotechnologies GmbH, Tübingen, Germany.
Jason J Luke *Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-1182-4908
Cedrik M Britten *Immatics Biotechnologies GmbH, Tübingen, Germany. cedrik.britten@immatics.com.ORCID http://orcid.org/0000-0003-3424-8760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40301562
PMCPMC12283359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.